Hologic - HOLX Stock Forecast, Price & News

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Bank of America downgraded Hologic from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $81.00 to $75.00 in a research report on Wednesday, July 20th. UBS Group started coverage on shares of Hologic in a research note on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price target on the stock. Citigroup cut their price target on shares of Hologic from $78.00 to $75.00 in a report on Thursday, April 28th. Wells Fargo & Company downgraded shares of Hologic from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $90.00 to $75.00 in a research report on Monday, April 25th. Finally, BTIG Research downgraded shares of Hologic from a "buy" rating to a "neutral" rating in a research report on Monday, July 18th. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $76.71.

Hologic Price Performance

HOLX Stock traded down $0.31 during mid-day trading on Thursday, hitting $71.58. 1,456,174 shares of the stock were exchanged, compared to its average volume of 1,787,752. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. The stock has a market capitalization of $17.87 billion, a price-to-earnings ratio of 12.08, a PEG ratio of 0.82 and a beta of 1.05. The business has a fifty day moving average price of $70.61 and a 200 day moving average price of $72.96. Hologic has a 12 month low of $66.58 and a 12 month high of $81.04.

Hologic (NASDAQ:HOLX - Get Rating) last issued its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $896.71 million. During the same period in the prior year, the business posted $1.33 EPS. Hologic's quarterly revenue was down 14.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Hologic will post 5.82 EPS for the current year.